Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight

globenewswire.com
AZN AstraZeneca is mentioned as the company with Symlin (pramlintide), an approved amylin analog used as an adjunct treatment for diabetes. The article discusses the broader landscape of amylin analogs and combination therapies, where AstraZeneca is a participant. LLY Eli Lilly and Company is listed as a key company in the Obesity Market Report and GLP-1 Agonists Market, and Type 2 Diabetes Market. The article discusses GLP-1 receptor agonists as a complementary therapy to amylin analogs, positioning Lilly as a significant player in related metabolic disorder treatments. NVO Novo Nordisk is mentioned as a key company in the Obesity Market Report, GLP-1 Agonists Market, Metabolic Dysfunction-Associated Steatohepatitis Market, Type 2 Diabetes Market, and Alzheimer's Disease Market. The article's focus on metabolic disorders and related therapies indirectly includes Novo Nordisk's market presence. PFE Pfizer is listed as a key company in the Obesity Market Report, Metabolic Dysfunction-Associated Steatohepatitis Market, and Type 2 Diabetes Market. The article's discussion of metabolic diseases and related drug development includes Pfizer as a participant. AMGN Amgen is mentioned as a key company in the GLP-1 Agonists Market. While not directly discussing Amgen's specific products in the context of amylin analogs, its inclusion in the GLP-1 market highlights its relevance to the broader metabolic disease space. BMY Bristol Myers Squibb is listed as a key company in the Alzheimer's Disease Market. The article mentions Alzheimer's disease pipeline combination therapies, indirectly linking BMS to the broader therapeutic areas discussed. JNJ Johnson & Johnson is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes JNJ in the context of broader therapeutic advancements. REGN Regeneron Pharmaceuticals is listed as a key company in the GLP-1 Agonists Market and Type 2 Diabetes Market. The article's focus on metabolic disorders and related therapies indirectly includes Regeneron's market presence. VKTX Viking Therapeutics is listed as a key company in the GLP-1 Agonists Market and Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Viking Therapeutics. ZETA Zealand Pharma is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Zealand Pharma. CRSP Corcept Therapeutics is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Corcept Therapeutics. IONS Ionis Pharmaceuticals is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Ionis Pharmaceuticals. AXSM Axsome Therapeutics is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes Axsome Therapeutics in the context of broader therapeutic advancements. MRK Merck & Co. is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Merck & Co. GSK GlaxoSmithKline is listed as a key company in the GLP-1 Agonists Market. The article's focus on metabolic disorders and related therapies indirectly includes GSK's market presence. SNY Sanofi is listed as a key company in the GLP-1 Agonists Market. The article's focus on metabolic disorders and related therapies indirectly includes Sanofi's market presence. IMUX Immuron Limited is listed as a key company in the Type 2 Diabetes Market. The article's discussion of metabolic diseases and related drug development includes Immuron Limited. BMEA Biomea Fusion Inc. is listed as a key company in the Type 2 Diabetes Market. The article's discussion of metabolic diseases and related drug development includes Biomea Fusion Inc. ALKS Alkermes is listed as a key company in the Obesity Market Report. The article's discussion of obesity and related drug development includes Alkermes. ALT Altimmune is listed as a key company in the Obesity Market Report. The article's discussion of obesity and related drug development includes Altimmune. AARD Aardvark Therapeutics is listed as a key company in the Obesity Market Report. The article's discussion of obesity and related drug development includes Aardvark Therapeutics. NOV Novartis is listed as a key company in the Obesity Market Report and Alzheimer's Disease Market. The article's discussion of obesity and Alzheimer's disease indirectly includes Novartis. CARM Carmot Therapeutics is listed as a key company in the Obesity Market Report and GLP-1 Agonists Market. The article's discussion of obesity and GLP-1 agonists indirectly includes Carmot Therapeutics. CRIS Cirius Therapeutics, Inc. is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Cirius Therapeutics. LPCN Lipocine Inc. is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Lipocine Inc. GILD Gilead Sciences is listed as a key company in the Metabolic Dysfunction-Associated Steatohepatitis Market. The article's discussion of metabolic diseases and related drug development includes Gilead Sciences. REG Regor Pharmaceuticals Inc. is listed as a key company in the Type 2 Diabetes Market. The article's discussion of metabolic diseases and related drug development includes Regor Pharmaceuticals Inc. SPRO Sparrow Pharmaceuticals is listed as a key company in the Type 2 Diabetes Market. The article's discussion of metabolic diseases and related drug development includes Sparrow Pharmaceuticals. ABSI AB Science is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes AB Science. ALZN Alzheon Inc. is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes Alzheon Inc. ANVS Annovis Bio, Inc. is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes Annovis Bio. BV BioVie is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes BioVie. ARCL Araclon Biotech S.L. is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes Araclon Biotech. ACIU AC Immune SA is listed as a key company in the Alzheimer's Disease Market. The article's mention of Alzheimer's disease pipeline combination therapies indirectly includes AC Immune SA.

Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight New York, USA, July 28, 2026 (GLOBE NEWSWIRE) -- Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight

The amylin analogs and combination therapies competitive landscape report delivers important insights into approved as well as ongoing research of 20+ pipeline amylin analogs and combination therapies, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s Amylin Analogs and Combination Therapies Competitive Landscape 2026 report provides comprehensive global coverage of approved and pipeline amylin analogs and combination therapies across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the amylin analogs and combination therapies domain.

Key Takeaways from the Amylin Analogs and Combination Therapies Pipeline Report

Request a sample and discover how has the approval of combination therapies impacted OPDIVO's market share @ https://www.delveinsight.com/report-store/amylin-analogs-and-combination-therapies-competitive-landscape

What are Amylin Analogs and Combination Therapies?

Amylin analogs are synthetic versions of amylin, a naturally occurring hormone co-secreted with insulin by pancreatic β-cells. Amylin plays a key role in regulating postprandial glucose levels by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety, thereby reducing food intake. In recent years, amylin analogs such as pramlintide and next-generation long-acting agents have gained significant attention for their potential in obesity and metabolic disorder management. Combination therapies involving amylin analogs and other metabolic agents, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, are emerging as a promising treatment strategy. These combinations leverage complementary mechanisms of action to enhance weight loss, improve glycemic control, and potentially offer superior efficacy compared to monotherapy. As clinical research advances, amylin-based combination therapies are expected to play an increasingly important role in the treatment landscape for obesity, type 2 diabetes, and related metabolic diseases.

To know more about amylin analogs and combination therapies, visit @ Obesity Combination Therapies

Approved Amylin Analogs and Combination Therapies Drug Profile Analysis

Symlin (pramlintide): AstraZeneca

Pramlintide is a laboratory-engineered analog of amylin that has been approved as an adjunct treatment to mealtime insulin for patients with both type 1 and type 2 diabetes mellitus. It was designed to replicate the physiological effects of amylin, a hormone normally released alongside insulin from pancreatic beta cells but often lacking in individuals with diabetes. By stimulating amylin receptors, pramlintide slows gastric emptying, reduces postprandial glucagon release, and promotes feelings of fullness, thereby supporting better regulation of blood glucose levels after meals. Commercially available under the brand name Symlin, it is administered via subcutaneous injection before eating.

Find out more about what's the best biotech company offering combination therapies with checkpoint inhibitors @ Amylin Analogs and Combination Therapies Analysis

A snapshot of the Pipeline Amylin Analogs and Combination Therapies mentioned in the report:

Learn more about the emerging amylin analogs and combination therapies @ Amylin Analogs and Combination Therapies Clinical Trials

Amylin analogs and amylin-based combination therapies are emerging as a promising next-generation obesity treatment class, offering complementary mechanisms to incretin therapies through enhanced satiety, delayed gastric emptying, and potential preservation of lean body mass. Combination approaches, particularly those integrating amylin receptor agonism with GLP-1 or other metabolic pathways, may deliver superior weight loss and improved tolerability, positioning them as strong contenders in the increasingly competitive obesity market.

Recent Developments in the Amylin Analogs and Combination Therapies Treatment Space

Scope of the Amylin Analogs and Combination Therapies Pipeline Report

Dive deep into rich insights for new amylin analogs and combination therapies for Alzheimer’s disease, visit @ Alzheimer’s Disease Pipeline Combination Therapies

Table of Contents

For further information on the amylin analogs and combination therapies pipeline therapeutics, reach out @ Amylin Analogs and Combination Therapies Therapeutics

Related Reports

Obesity Market Report

Obesity Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

GLP-1 Agonists Market

GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GLP-1 agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.

Metabolic Dysfunction-Associated Steatohepatitis Market

Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, and others.

Type 2 Diabetes Market

Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide, Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, and other.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.